GLP1R and diabetes mellitus: Several glucose-lowering medications from three novel classes have been approved in the USA for use in adult patients with diabetes: glucagon-like peptide-1 (GLP1) receptor agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and sodium glucose cotransporter-2 (SGLT2) inhibitors [71], many of which have beneficial effects on kidney outcomes [69].